Answers are grounded in this paper and cite their sources.
Hairy cell leukemia variant (HCL-V) is now included in the World Health Organization (WHO) classification as a provisional entity and is no longer considered to be biologically related to classic HCL (HCL-C). The clinical course of HCL-V is variable but usually more aggressive, and the median survival of patients with HCL-V is significantly shorter than that of HCL-C. The therapeutic approach to HCL-V is still debated. Various treatment approaches active in HCL-C achieve partial response (PR) or no response in HCL-V, and remission is usually shorter than in HCL-C. In addition, HCL-V seems to be resistant to therapeutic modalities usually highly effective in the treatment of HCL-C. Cladribine (2-CdA) is significantly less active in HCL-V than in HCL-C. In addition, the majority of patients with HCL-V require more than one cycle of 2-CdA to maintain PR. Patients with HCL-V treated with pentostatin also have a poorer clinical outcome and a lower response rate than those of patients with HCL-C. Recently, some reports indicate that monoclonal antibodies, rituximab and alemtuzumab, are active in HCL-V. Promising results have also been obtained with anti-CD22 immunotoxin, BL22. A new generation of CD22-specific immunotoxins, moxetumomab pasudotox (CAT-8015, HA22), highly active in refractory/relapsed HCL-C, also need clinical investigation in HCL-V. Currently, immunochemotherapy with rituximab and purine nucleoside analogs (PNAs) should be considered as the treatment of choice in previously untreated patients.
No takes yet. Share an insight, caveat, or question.
Tadeusz Robak (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: